Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView
Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView multimodality workstation to provide quantitative and reproducible methods of image analysis. Molecular imaging promises exact and sensitive information, leading to earlier and more accurate diagnoses-but only if the data can be quantified, according to the two companies. Although Mirada has established relationships with hardware manufacturers, this is its first with a company engaged primarily in pharmaceuticals.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.